Today: 20 March 2026
Subscribe
Browse Category

NASDAQ:MGTX 10 November 2025

Eli Lilly (LLY) Pops on Fresh Deal Spree: MeiraGTx Gene Therapy Tie‑Up, New AI Collaboration, and Leerink Upgrade — Nov. 10, 2025

Eli Lilly (LLY) Pops on Fresh Deal Spree: MeiraGTx Gene Therapy Tie‑Up, New AI Collaboration, and Leerink Upgrade — Nov. 10, 2025

Eli Lilly agreed to pay $75 million upfront and over $400 million in milestones for global rights to MeiraGTx’s pediatric blindness gene therapy. The company also announced an AI drug discovery partnership with Insilico Medicine, worth over $100 million in potential payments. Leerink Partners upgraded Lilly shares and raised its price target to $1,104, sending the stock up about 5% intraday.
10 November 2025
······

Stock Market Today

  • Evertz Technologies Fair Value Targets Lifted by Analysts on TSX
    March 20, 2026, 2:37 PM EDT. Analysts have raised the fair value estimate for Evertz Technologies (TSX:ET) from CA$14.88 to CA$17.25, reflecting a roughly 16% increase and aligning with a cluster of price targets between CA$16 and CA$17.50. Canaccord and BMO Capital have each lifted their price targets to CA$17.50, maintaining positive ratings, while RBC Capital has raised its target incrementally to CA$16 but retains a cautious Sector Perform stance. The upward revisions follow updated assumptions, including a slight dip in revenue growth to 4.16% and an improved net profit margin to 12.98%. The stock's quarterly dividend was declared at CA$0.2050 per share, payable March 2026. Investors should note the narrowed upside range and potential risks flagged, advising careful consideration of entry points and expectations.
Go toTop